The impact of centralised care of younger AML patients on treatment results: a retrospective analysis of real-world data from a national population-based registry

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Science. Official publication website can be found on muni.cz.

Authors	SEMERAD Lukas SUSTKOVA Zuzana CETKOVSKY Petr JINDRA Pavel KORISTEK Zdenek NOVAK Jan RACIL Zdenek SZOTKOWSKI Tomas WEINBERGEROVA Barbora ZAK Pavel POSPÍŠIL Zdeněk BARANOVA Jana MAYER Jiri
Year of publication	2021
Type	Article in Periodical
Magazine / Source	Acta Oncologica
MU Faculty or unit	Faculty of Science
Citation
Web	https://www.tandfonline.com/doi/full/10.1080/0284186X.2021.1917002
Doi	http://dx.doi.org/10.1080/0284186X.2021.1917002
Keywords	ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; HOSPITAL VOLUME; MORTALITY; CHEMOTHERAPY; OUTCOMES
Description	The care for younger patients with acute myeloid leukaemia (AML) requires fully equipped medical facilities that have routine experience with the management of this aggressive disorder. Two independent analyses of real-world data from the United States (US) have showed a lower early mortality after an intensive chemotherapy when the patients are treated in high-volume centres or in National Cancer Institution-Designated Cancer Centres (NCI-CC) compared to the treatment in low-volume or in non-NCI-CC centres [1,2].